10,249
Total Claims
$3.1M
Drug Cost
1,091
Beneficiaries
$2,881
Cost/Patient
Peer Comparison vs. 18,720 Cardiology providers
+89%
Cost per patient vs peers
$2,881 vs $1,524 avg
Brand vs Generic
100% generic
Brand: 0 claims · $0
Generic: 8,657 claims · $272K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Tafamidis | 20 | $921K |
| Apixaban | 598 | $736K |
| Rivaroxaban | 169 | $232K |
| Dapagliflozin Propanediol | 143 | $201K |
| Sacubitril/Valsartan | 159 | $178K |
| Empagliflozin | 72 | $114K |
| Mavacamten | 14 | $111K |
| Alirocumab | 112 | $106K |
| Semaglutide | 68 | $84K |
| Dronedarone Hcl | 17 | $38K |
| Icosapent Ethyl | 31 | $29K |
| Icosapent Ethyl | 66 | $29K |
| Rosuvastatin Calcium | 1,101 | $23K |
| Pitavastatin Calcium | 26 | $22K |
| Ezetimibe | 398 | $19K |
Prescribing Profile
Patient Profile
77
Avg Age
46%
Female
1.37
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data